![Maat Pharma and Skyepharma have entered a partnership to establish the first exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France](https://www.seventure.fr/wp-content/uploads/2018/10/4__104270789-322x211.jpg)
14 February 2022
Maat Pharma and Skyepharma have entered a partnership to establish the first exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
MaaT Pharma (EURONEXT: MAAT), a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival...